THE EFFICACY AND SAFETY OF ORAL AZACITIDINE PLUS BEST SUPPORTIVE CARE VERSUS PLACEBO AND BEST SUPPORTIVE CARE IN SUBJECTS WITH RED BLOOD CELL (RBC) TRANSFUSION-DEPENDENT ANEMIA AND THROMBOCYTOPENIA DUE TO INTERNATIONAL PROGNOSTIC SCORING SYSTEM (IPSS) LOW RISK MYELODYSPLASTIC SYNDROME (MDS):